|
gptkbp:instanceOf
|
gptkb:antipsychotic_medication
gptkb:brand
|
|
gptkbp:actsOn
|
adrenergic receptors
dopamine receptors
histamine receptors
muscarinic receptors
serotonin receptors
|
|
gptkbp:affiliatedWith
|
phenothiazines
|
|
gptkbp:ATCCode
|
N05AA01
|
|
gptkbp:CASNumber
|
50-53-3
|
|
gptkbp:chemicalFormula
|
C17H19ClN2S
|
|
gptkbp:contraindication
|
bone marrow depression
severe CNS depression
|
|
gptkbp:discoveredBy
|
gptkb:Paul_Charpentier
|
|
gptkbp:eliminationHalfLife
|
30 hours
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
gptkbp:firstAntipsychotic
|
true
|
|
gptkbp:genericName
|
gptkb:chlorpromazine
|
|
gptkbp:introducedIn
|
1950
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Smith_Kline_&_French
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular
intravenous
|
|
gptkbp:sideEffect
|
constipation
blurred vision
weight gain
drowsiness
dry mouth
extrapyramidal symptoms
neuroleptic malignant syndrome
tardive dyskinesia
|
|
gptkbp:synonym
|
gptkb:Chlorpromazine_hydrochloride
gptkb:Hibernal
gptkb:Largactil
gptkb:Sonazine
Megaphen
|
|
gptkbp:usedFor
|
gptkb:porphyria
bipolar disorder
nausea
schizophrenia
vomiting
tetanus
psychotic disorders
severe behavioral problems in children
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
true
|
|
gptkbp:bfsParent
|
gptkb:Smith,_Kline_&_French
|
|
gptkbp:bfsLayer
|
5
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Thorazine
|